Affordable Access

Publisher Website

Molecular biomarkers in drug development

Authors
Journal
Drug Discovery Today
1359-6446
Publisher
Elsevier
Publication Date
Volume
9
Issue
22
Identifiers
DOI: 10.1016/s1359-6446(04)03272-6
Keywords
  • Research Focus
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Arguably, the most immediately promising reverberation of the genomics era has been the application of biomarkers to drug development. The promise of applying biomarkers to early drug development is that they might aid in preclinical and early clinical decisions such as dose ranging, definition of treatment regimen, or even a preview of efficacy. Later in the clinic, biomarkers could be used to facilitate patient stratification, selection and the description of surrogate endpoints. Information derived from biomarkers should result in a better understanding of preclinical and clinical data, which ultimately benefits patients and drug developers. If the promise of biomarkers is realized, they will become a routine component of drug development and companions to newly discovered therapies.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Molecular biomarkers in drug development.

on Drug Discovery Today Nov 15, 2004

[Development of biomarkers for molecular target dr...

on Nihon rinsho. Japanese journal... August 2015

Biomarkers in drug development.

on Annals of Oncology July 2008

Leveling the playing field: bringing development o...

on Clinical Cancer Research Mar 15, 2012
More articles like this..